Active — Not RecruitingNot Applicable

Evaluation of Spasticity, Neuropathic Pain, and Gait Analysis in Stroke Patients Receiving Tolperison Therapy After Botulinum Toxin Injection

Turkey (Türkiye)40 participantsStarted 2025-08-13

Plain-language summary

Tolperison is an antispastic agent used in the treatment of spasticity. Studies on tolperison are limited, and the literature on its effectiveness against spasticity and neuropathic pain is also limited.

Who can participate

Age range18 Months – 80 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ability to stand * History of previous hemorrhagic or ischemic stroke * Stroke-related spasticity (MAS ≥2) * Men and women aged 18-80 years * Agreement to participate in the study Exclusion Criteria: * Diabetes patients * people who have undergone orthopedic surgery * Individuals with non-stroke neurological diseases * Those receiving oral antispastic treatment (non-tolperison medications) * Those who have undergone surgery for spasticity * Individuals lacking orientation and cooperation * Those undergoing surgery, such as with intrathecal baclofen * Individuals receiving medical treatment for neuropathic pain * Individuals under 18 and over 80 years of age * History of allergy or hypersensitivity to the medication to be used * Presence of a fixed contracture in the affected extremity

What they're measuring

Modified Ashworth Scale(MAS)

Timeframe: Time Frame: Baseline (Day O), Day 15, Month 1, and Month 3.

Douleur Neuropathique 4 (DN4)

Timeframe: Time Frame: Baseline (Day O), Day 15, Month 1, and Month 3.

Trial details

NCT IDNCT07482618

SponsorAyse Guc

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2026-05-25

View on ClinicalTrials.gov More Spastic Hemiplegia trials